Funding Cuts Threaten Cancer Immunotherapies
Researcher Miriam Merad warns that NIH funding cuts could hinder life-saving cancer research, particularly in the development of new immune cell-based therapies.
Macrophages, known as the body's "guardians," play a crucial role in detecting and clearing damage from organs and tissues. However, they can also weaken inflammation, undermining immune cells that attack tumor cells.
By weakening inflammation, they can undermine immune cells that attack tumor cells.
Oncologist Miriam Merad is dedicated to understanding how to adapt the powers of immune cells, including T cells and macrophages, to improve current immunotherapies. The scientific challenge is significant, and new obstacles, such as funding cuts, pose a great concern.
- 40% of National Institutes of Health grant dollars are being cut.
- These cuts threaten to derail research, including Merad's work at the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai.
Author's summary: Funding cuts threaten cancer research progress.
More News
- “They’re Not Welcome”: How Chicago Residents Are Resisting Trump’s ICE Invasion of the City
- 'Time was right': Maskell Medal winner makes league switch ahead of 2026 season
- Armenians in Jerusalem and the dilemma of Israel's recognition of the Armenian Genocide
- EU Unveils Major Defense Plan to Strengthen Eastern Borders and Counter Drone Threats by 2030 - EconoTimes
- India Gaming Awards 2025 honor top creators as dentsu and IWMBuzz reveal report
- Three in four doctors concerned about health impacts of climate change: physicians warn ‘the NHS is simply not prepared’
- Megyn Kelly Threatens to Run for President if AOC Does: 'F--k That Woman' | Video
- Campus Ministry Hosts First-Ever FRASSATI FEST -
- ‘Through continued international cooperation, we can eradicate world hunger once and for all’ – MO*